

ASX RELEASE

31 August 2022

AMPLIA RECEIVES \$1.8m R&D TAX INCENTIVE

Amplia Therapeutics Limited (ASX: ATX) (“Amplia” or the “Company”) wishes to advise that it has received a Research and Development Tax Incentive Refund of \$1,843,003.65 for the 2021/2022 financial year. The refund recognizes expenditure incurred in research and development associated with the Company’s FAK inhibitors, AMP945 and AMP886.

These R&D activities primarily related to the Company’s Phase 1b/2a ACCENT clinical trial of AMP945 in first-line pancreatic cancer patients, toxicology studies supporting longer-term dosing of AMP945 and further manufacturing development work.

The Australian Government’s Research and Development Tax Incentive Refund provides eligible companies with cash refunds for 43.5% of eligible expenditure on research and development activities.

This ASX announcement has been approved and authorised for release by the CEO of Amplia Therapeutics.

- End -

For Further Information

Dr. John Lambert

CEO and Managing Director

john@ampliatx.com

www.ampliatx.com

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).